At a glance
ClinicalIndex Comparison Record- ✓Adults with refractory or relapsed multiple myeloma
- ✓ECOG performance status 0–2
- ✓Adequate bone marrow reserve
- ✓Adequate hepatic and renal function
- ✕Planned bone marrow transplant within 4 weeks of treatment start
- ✕Prior treatment with other investigational agents with similar anti-tumor mechanism
- ✕Active/uncontrolled clinically significant illness
- ✕Pregnant or nursing
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Clinical Trial of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating vorinostat and bortezomib for Multiple Myeloma. Completed, enrolled 34 participants.
Detailed Summary
The purposes of this study are: * To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma * To assess the safety and tolerability of this regimen and to document the participant's clinical status (by anti-tumor activity) for this combination, as determined per standard of care.
Study Details
Timeline
Interventions
Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.